{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113762.1.4.1196.468",
  "meta" : {
    "versionId" : "16",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "NHLBI Implementation Science and Health Care Innovation Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2024-06-03"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2021-09-09"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.468",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113762.1.4.1196.468"
    }
  ],
  "version" : "20210909",
  "name" : "ZileutonOralPreparations",
  "title" : "Zileuton Oral Preparations",
  "status" : "retired",
  "experimental" : false,
  "date" : "2021-09-09T01:00:51-04:00",
  "publisher" : "NHLBI Implementation Science and Health Care Innovation Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This valueset is intended to capture oral zileuton preparations that are used for maintenance therapy in asthmatic adults and children 12+ years of age as per the NHLBI NAEPP EPR3 Guidelines for the Diagnosis and Management of Asthma (2007) and associated Summary Report and Quick Reference Guide and the 2020 Focused Updates to the Asthma Management Guidelines.  Zileuton is the only leukotriene synthesis inhibitor available, and acts by blocking 5-lipoxygenase activity.),(Data Element Scope: FHIR \nMedicationStatement.medicationCodeableConcept, MedicationRequest.medicationCodeableConcept),(Inclusion Criteria: zileuton oral products),(Exclusion Criteria: Excludes withdrawn preparations and retired codes (although they may still be available from pharmacies until supplies are exhausted))",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept" : [
          {
            "code" : "199904",
            "display" : "zileuton 600 MG Oral Tablet"
          },
          {
            "code" : "211777",
            "display" : "zileuton 600 MG Oral Tablet [Zyflo]"
          },
          {
            "code" : "730834",
            "display" : "12 HR zileuton 600 MG Extended Release Oral Tablet"
          },
          {
            "code" : "790889",
            "display" : "12 HR zileuton 600 MG Extended Release Oral Tablet [Zyflo]"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:285b03be-fc06-42c8-a986-7c397cf1a049",
    "timestamp" : "2024-06-14T13:17:02-04:00",
    "total" : 4,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "199904",
        "display" : "zileuton 600 MG Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "211777",
        "display" : "zileuton 600 MG Oral Tablet [Zyflo]"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "730834",
        "display" : "12 HR zileuton 600 MG Extended Release Oral Tablet"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "05062024",
        "code" : "790889",
        "display" : "12 HR zileuton 600 MG Extended Release Oral Tablet [Zyflo]"
      }
    ]
  }
}
